Vitamin D Deficiency Clinical Trial
Official title:
The Contribution of Vitamin D to Muscle Metabolic Function in Cancer Cachexia
Verified date | October 2020 |
Source | University of Kentucky |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study is aimed at examining mitochondrial function as a potential target of action of vitamin D on muscle metabolism, size, and strength in preventing the progression of cachexia. This is the first clinical trial designed to understand the effects of vitamin D on muscle metabolic dynamics driving dysfunction in cachectic muscle. Our preliminary data suggest that vitamin D promotes lipid partitioning and muscle metabolic function, which the investigators hypothesize, will mitigate cachexia via improved muscle health and quality that translates into reduced fatigue, and improved patient resilience to multimodal cancer therapy.
Status | Completed |
Enrollment | 1 |
Est. completion date | September 13, 2018 |
Est. primary completion date | September 13, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility |
Inclusion Criteria: Patients must have histologically or cytologically confirmed stage II-IV lung cancer and be planned for definitive non-surgical therapy. Patients may have a history of prior malignancy. Mild cancer cachexia, defined by the miniCASCO score of 0-25 points Vitamin D insufficiency, defined as 25(OH)D < 32 ng/ml Aged 45 to 75 years. Stratified randomization by age ECOG performance status = 2 (see Appendix A). Life expectancy of greater than 3 months Patients must have normal renal and liver function as defined below: AST(SGOT)/ALT(SGPT) =2.5 × institutional upper limit of normal creatinine within normal institutional limits OR creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. Able to swallow thin liquids No uncontrolled illness including, but not limited to, any of the following: - Ongoing or active serious infection - Symptomatic congestive heart failure - Unstable angina pectoris - Uncontrolled cardiac arrhythmia - Uncontrolled hypertension - Psychiatric illness or social situation that would preclude compliance with study requirements Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Patients with untreated brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with treated brain metastasis are eligible for this trial, providing they have completed treatment at least one day prior to registration. History of allergic reactions to whey or milk proteins. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with a history of calcium oxalate nephrolithiasis are excluded. Patients with a significant history of malabsorption (e.g. celiac sprue, short bowel syndrome, IBD or other, as determined by the treating physician) are excluded. Patients will not be eligible if actively receiving treatment for vitamin D deficiency and have had recent (3 month) history of vitamin D supplementation (>1000 IU) or calcium supplementation (>800mg). The following exclusion criteria will avoid the possibility of preexisting muscle impairment: history of congenital myopathies; neurologic disorder involving sequelae of spinal derangement; disk disease or vascular disease; tremor and rigidity. Patients will also be excluded if they report lower extremity (LE) surgery or injury to the LE in the past 3 months or a past medical history of primary hyperparathyroidism; or rhabdomyolysis. Additional exclusion criteria include participation in a scheduled resistance exercise program 1 month; - metal implants or other contraindications for the MRI; - diabetes, - advanced renal disease, - uncontrolled hypertension; - a vitamin D status (25(OH)D) of > 32ng/mL. |
Country | Name | City | State |
---|---|---|---|
United States | Markey Cancer Center | Lexington | Kentucky |
Lead Sponsor | Collaborator |
---|---|
David Travis Thomas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-invasive quantification of muscle lipid distribution | MRI/MRS | Change between Week 0 and Week 12 | |
Primary | Local muscle oxygen consumption | Near Infrared Spectroscopy + Diffuse Correlation Spectroscopy measures will be combined to assess changes in local muscle tissue oxygen consumption (VO2 measure) | Change between Week 0 and Week 12 | |
Primary | Muscle Mass | MRI | Change between Week 0 and Week 12 | |
Primary | Muscle Strength | Maximal voluntary contractions and 1-Repetition Maximum will be aggregated to to provide a comprehensive assessment of muscle strength | Change between Week 0, Week 6, Week 12 | |
Secondary | Mitochondrial Function in Muscle Fibers in Fresh Muscle Fibers ex vivo | Determine the differences in muscle mitochondrial function in live tissue biopsied from human gastrocnemius from VitD compared to Ctl by measure live tissue oxygen consumption rate. Respiration measures will be combined to assess mitochondrial function Mitochondrial respiration will be measured by the XF96 Seahorse extracellular flux analyzer |
Experiments will be conducted from tissue collected at week 12 study biopsy | |
Secondary | Mitochondrial Function in Muscle Fibers in Fresh Muscle Fibers ex vivo | Determine the differences in muscle mitochondrial function in live tissue biopsied from human gastrocnemius from VitD compared to Ctl by measure live tissue oxygen consumption rate. Fatty acid oxidation measures will be combined to assess mitochondrial function Fatty acid oxidation will be estimated by monitoring the OCR of cells with no exogenous glucose or glutamine (Gln) ± a specific fatty acid oxidation (FAO) inhibitor, etomoxir (40 µM) |
Experiments will be conducted from tissue collected at week 12 study biopsy | |
Secondary | Stable Isotope-Resolved Metabolomics to describe Fatty Acid Metabolism in relationship to other fuel substrates in Fresh Muscle Fibers ex vivo | Determine the relative importance of vitamin D on lipid, amino acid and energy metabolism involving glucose, glutamine, and ß-oxidation in intact muscle fibers. We will culture with 13C8-octanoate, 13C6-glucose, or 13C5-Gln and measure metabolite isotopomer distributions to accomplish this goal. | Experiments will be conducted from live tissue collected at week 12 study biopsy | |
Secondary | Utilize cell culture experimentation to understand anabolic signaling in response to vitamin D with or without fiber stretch. | Identify mechanisms whereby vitamin D and RE regulate anabolic signaling in primary human myotube cultures. Changes in signaling pathways associated with hypertrophy, including Akt, mTOR, MAPK, and AMPK, will be measured by phospho-western blot to determine response to calcitriol, palmitate, and stretch treatment in myotubes. | Experiments will be conducted from tissue collected at week 12 study biopsy | |
Secondary | Utilize cell culture experimentation to measure mitochondrial activity in response to vitamin D with or without fiber stretch. | To understand how vitamin D and RE regulate mitochondrial activity in primary human myotube cultures, the investigators will measure extracellular acidification rate (ECAR) in response to calcitriol supplementation. This will be assessed through the addition of CPT-1 inhibitor etomoxir (40 µM) and the ATP-synthase inhibitor oligomycin | Experiments will be conducted from tissue collected at week 12 study biopsy | |
Secondary | Utilize cell culture experimentation to measure mitochondrial activity in response to vitamin D with or without fiber stretch. | Identify mechanisms whereby vitamin D and RE regulate mitochondrial activity in primary human myotube cultures. The investigators will measure the concentration of ATP in myotubes in response to calcitriol supplementation. |
Experiments will be conducted from tissue collected at week 12 study biopsy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 |